Identifying the lower age limit for hepatitis C screening in large elimination programmes in highly endemic areas

Saeed Hamid; Adeel Abid; Gregory J. Dore

doi:10.1016/S2468-1253(20)30371-X

Identifying the lower age limit for hepatitis C screening in large elimination programmes in highly endemic areas

Saeed Hamid
, Adeel Abid
, Gregory J. Dore

Department of Medicine, Medical College, Pakistan

Research output: Contribution to journal › Letter › peer-review

5 Citations (Scopus)

Original language	English (UK)
Pages (from-to)	89-90
Number of pages	2
Journal	The Lancet Gastroenterology and Hepatology
Volume	6
Issue number	2
DOIs	https://doi.org/10.1016/S2468-1253(20)30371-X
Publication status	Published - Feb 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/S2468-1253(20)30371-X

Cite this

@article{b5ae63a3680f4effb9fdc2f4a7c51d6a,

title = "Identifying the lower age limit for hepatitis C screening in large elimination programmes in highly endemic areas",

author = "Saeed Hamid and Adeel Abid and Dore, \{Gregory J.\}",

note = "Funding Information: GJD reports grants from Gilead, AbbVie, Merck, and Bristol-Myers Squibb, personal fees from Gilead, AbbVie, and Merck, and non-financial support from Gilead, AbbVie, and Merck, outside the submitted work. Study funded by Gilead Sciences through the CHIME grant programme. SH and AA declare no competing interests. ",

year = "2021",

month = feb,

doi = "10.1016/S2468-1253(20)30371-X",

language = "English (UK)",

volume = "6",

pages = "89--90",

journal = "The Lancet Gastroenterology and Hepatology",

issn = "2468-1253",

publisher = "Elsevier Ltd.",

number = "2",

}

TY - JOUR

T1 - Identifying the lower age limit for hepatitis C screening in large elimination programmes in highly endemic areas

AU - Hamid, Saeed

AU - Abid, Adeel

AU - Dore, Gregory J.

N1 - Funding Information: GJD reports grants from Gilead, AbbVie, Merck, and Bristol-Myers Squibb, personal fees from Gilead, AbbVie, and Merck, and non-financial support from Gilead, AbbVie, and Merck, outside the submitted work. Study funded by Gilead Sciences through the CHIME grant programme. SH and AA declare no competing interests.

PY - 2021/2

Y1 - 2021/2

UR - https://www.scopus.com/pages/publications/85099214763

U2 - 10.1016/S2468-1253(20)30371-X

DO - 10.1016/S2468-1253(20)30371-X

M3 - Letter

C2 - 33444535

AN - SCOPUS:85099214763

SN - 2468-1253

VL - 6

SP - 89

EP - 90

JO - The Lancet Gastroenterology and Hepatology

JF - The Lancet Gastroenterology and Hepatology

IS - 2

ER -

Identifying the lower age limit for hepatitis C screening in large elimination programmes in highly endemic areas

UN SDGs

Access to Document

Other files and links

Cite this